Is PharmaCyte Biotech Inc (PMCB) overvalued? · $8.6M cap
PharmaCyte Biotech Inc (PMCB) is a biotechnology company listed on NASDAQ.
This page asks whether PharmaCyte Biotech Inc (PMCB) looks expensive on cached numbers — not a short thesis.
Latest reported PMCB revenue for 2025-04-30 was $0. Net income was $30.7M. PMCB currently screens at market cap $8.6M.
PMCB currently screens at market cap $8.6M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next PMCB 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the PMCB stock page for the full model, not this heading.
Not investment advice.